Vapotherm Inc Closes $20 Million Series C Financing Round - Gilde Healthcare

Vapotherm Inc Closes $20 Million Series C Financing Round

March 13, 2015

EXETER, NH – Vapotherm, Inc., a developer and manufacturer of advanced respiratory care technology, today announced the closing of a $20MM equity financing. 3×5 Specialty Opportunity Fund led the financing round, which also included current investors QuestMark Partners, Gilde Healthcare Partners, Morgenthaler Ventures, Kaiser Permanente, Adage Capital Management, Crestline Investors and Cross Creek Capital.

Tony Arnerich General Partner of 3×5 Special Opportunity Fund commented: “We are excited about Vapotherm’s unique High Flow Therapy solution which improves clinical outcomes for patients with chronic and acute breathing disorders.”

“This new capital will be used to continue to build out our direct sales organization in the U.S. and to develop our next generation solutions. We appreciate the continued support of our investors as we build a leading respiratory care company,” said Joe Army, President and CEO of Vapotherm.

Vapotherm, Inc. is a privately held developer and manufacturer of advanced respiratory care technology based in Exeter, New Hampshire. The company develops innovative, comfortable, noninvasive technologies for respiratory support of patients with chronic or acute breathing disorders. Over 700,000 patients have been treated with Vapotherm High Flow Therapy. For more information, visit www.vtherm.com.

Contact: John Landry, VP & CFO
T: (603) 658-0011

Gilde Healthcare company Big Health builds out its Leadership Team with the appointment of five key Executives

Big Health, creators of the leading digital treatments for mental health, has appointed five executives to its senior leadership team as the company enters the next phase in the growth of its business. This follows...
January 12, 2023

Gilde Healthcare company Volta medical secures €36M in Series B funding

Volta Medical, a pioneering health technology company developing artificial intelligence (AI) solutions to assist electrophysiologist physicians in treating complex cardiac arrhythmias such as atrial fibrillation (AF), today announced €36 million in new Series B funding,...
January 5, 2023

Gilde Healthcare company Adcendo Aps Announces License Agreement with Duality Biologics on Next-generation ADC Platform

Adcendo licenses Duality’s DITAC (Duality Immune Toxin Antibody Conjugates) linker/payload platform for its lead uPARAP-ADC program Agreement based on synergies between Adcendo and Duality in generating breakthrough ADCs in hard-to-treat cancers Adcendo ApS (“Adcendo”), a...
January 5, 2023